Luoxin Pharmaceuticals Group Stock Co., Ltd.

Equities

002793

CNE1000026S7

Pharmaceuticals

End-of-day quote Shenzhen S.E. 18:00:00 2024-05-13 EDT 5-day change 1st Jan Change
4.88 CNY +2.95% Intraday chart for Luoxin Pharmaceuticals Group Stock Co., Ltd. +5.86% -8.96%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Luoxin Pharma Gets Right to Use Shenzhen Shishijijun Biotechnology's Fecal Microbiota Transplant Technology MT
Tranche Update on Luoxin Pharmaceuticals Group Stock Co., Ltd.'s Equity Buyback Plan announced on February 2, 2024. CI
Luoxin Pharmaceuticals Group Stock Co., Ltd.'s Equity Buyback announced on February 2, 2024, has closed with 26,027,861 shares, representing 2.39% for CNY 99.99 million. CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. announces an Equity Buyback for CNY 100 million worth of its shares. CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. authorizes a Buyback Plan. CI
Luoxin Pharmaceuticals Posts Positive Results of Plucanatide Tablets' Trial MT
Two Luoxin Pharma Drugs Selected in China’s National Drug Procurement Program MT
Luoxin Health Technology Development Co., Ltd. announced that it has received CNY 5.7 million in funding from Luoxin Pharmaceuticals Group Stock Co., Ltd. CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Luoxin Pharmaceuticals Group Stock Co., Ltd.'s LX-039 (Innovative Anti-Tumor Drug) Phase I Clinical Study Data Presented At ESMO 2023 CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. agreed to acquire additional unknown stake in Luoxin Health Technology Development Co., Ltd. from Chengdu Deyi Xinhua Equity Investment Partnership Enterprise (LP) and Deyi Investment Management Co., Ltd. for CNY 1. CI
Luoxin Health Technology Development Co., Ltd. announced that it expects to receive CNY 5.7 million in funding from Luoxin Pharmaceuticals Group Stock Co., Ltd. CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. Elects Li Meng as Non-Independent Directors CI
Luoxin Pharmaceuticals' Injection Passes Regulatory Consistency Evaluation MT
Luoxin Pharmaceuticals Gets Regulatory Nod for Anti-Baterial Infection Drug MT
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Luoxin Pharmaceuticals Unit Plans to Sell Stake in Medical Equipment Firm CI
Luoxin Health Technology Development Co., Ltd. announced that it expects to receive CNY 127.9 million in funding from Deyi Investment Management Co., Ltd., Luoxin Pharmaceuticals Group Stock Co., Ltd. CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2021, Payable on May 13, 2022 CI
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Chart Luoxin Pharmaceuticals Group Stock Co., Ltd.
More charts
Luoxin Pharmaceuticals Group Stock Co Ltd, formerly Zhejiang Doyin Pump Industry Co Ltd, is a China-based company mainly engaged in the research and development, manufacturing and sales of pharmaceutical products. The Company operates two segments. The Pharmaceutical Industry segment is engaged in the research and development, manufacturing and sales of chemical drug preparations and raw and auxiliary drugs. Its main products are digestive drugs, respiratory drugs and antibiotic drugs, among others. The Pharmaceutical Business segment is engaged in the sales and logistics of agent drugs and medical devices. The Company conducts its businesses in the domestic market.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 002793 Stock
  4. News Luoxin Pharmaceuticals Group Stock Co., Ltd.
  5. Luoxin Pharmaceuticals Posts Positive Results of Plucanatide Tablets' Trial
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW